## Bilge Piri Cinar

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4733812/bilge-piri-cinar-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

21	151	8	12
papers	citations	h-index	g-index
23	191	<b>2.7</b> avg, IF	2.85
ext. papers	ext. citations		L-index

#	Paper	IF	Citations
21	Thyroid functions as a parameter in monitoring of antiepileptic drugs Neurological Research, 2022, 1-8	2.7	
20	Clinical-epidemiological and radiological characteristics of stroke patients: A multicentre study. <i>International Journal of Clinical Practice</i> , <b>2021</b> , e14963	2.9	0
19	The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14158	2.9	O
18	A comprehensive assessment of patient experience and disease-related awareness in multiple sclerosis: A questionnaire-based nation-wide survey in Turkey. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 52, 103005	4	1
17	Assessment of the relation between the neutrophil to lymphocyte ratio and severity of ischemic stroke in a large cohort. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13955	2.9	0
16	Effects of androgen deprivation therapy on cognitive functions in patients with metastatic prostate cancer: A multicentric, prospective study of the Society of Urological Surgery Andrology group. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e14095	2.9	2
15	The 20-year history: Change of multiple sclerosis patient profile over 20 years. <i>Multiple Sclerosis and Related Disorders</i> , <b>2019</b> , 33, 1-4	4	2
14	Monthly Pulse Methylprednisolone Therapy is Effective in Preventing Permanent Disease Progression in Secondary Progressive Multiple Sclerosis. <i>Noropsikiyatri Arsivi</i> , <b>2019</b> , 56, 115-118	0.6	1
13	The reducing effect of agomelatine on pentylenetetrazol-induced convulsions. <i>Biologia Futura</i> , <b>2019</b> , 70, 336-340	1	
12	What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale. <i>Noropsikiyatri Arsivi</i> , <b>2018</b> , 55, S69-S75	0.6	15
11	A Rare Cause of Reversible Splenial Lesion Syndrome: A Case Report with Epilepsy. <i>Balkan Medical Journal</i> , <b>2018</b> , 35, 122-123	1.5	1
10	Neuroprotective effects of octreotide on diabetic neuropathy in rats. <i>Biomedicine and Pharmacotherapy</i> , <b>2017</b> , 89, 468-472	7.5	8
9	Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results. <i>Clinical Neurology and Neurosurgery</i> , <b>2017</b> , 160, 27-29	2	12
8	The Turkish validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery. <i>BMC Neurology</i> , <b>2017</b> , 17, 208	3.1	24
7	Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial. <i>Clinical Neurology and Neurosurgery</i> , <b>2017</b> , 160, 69-72	2	5
6	Oxytocin provides protection against diabetic polyneuropathy in rats. <i>Neurological Research</i> , <b>2017</b> , 39, 45-53	2.7	19
5	Cognitive dysfunction in patients with multiple sclerosis treated with first-line disease-modifying therapy: a multi-center, controlled study using the BICAMS battery. <i>Neurological Sciences</i> , <b>2017</b> , 38, 337	·-3·42	13

## LIST OF PUBLICATIONS

4	Inhibitor effect of paricalcitol in rat model of pentylenetetrazol-induced seizures. <i>Naunyn-Schmiedeberg Archives of Pharmacology</i> , <b>2016</b> , 389, 1117-22	3.4	9
3	Paced auditory serial addition test: National normative data. <i>Clinical Neurology and Neurosurgery</i> , <b>2016</b> , 140, 97-9	2	6
2	The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. <i>Neuropeptides</i> , <b>2015</b> , 49, 1-5	3.3	29
1	Evaluation of clinical parameters during and after treatment of attack in patients with clinically isolated syndrome: comparison of the results with that of multiple sclerosis patients. <i>Clinical Neurology and Neurosurgery</i> , <b>2013</b> , 115, 2432-7	2	4